This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Preparing for the FDA Panel on Aducanumab: What might panel members, the agency, and physicians be thinking about Biogen's application days before the Ad-com?

Ticker(s): BIIB

Who's the expert?

Name: Dr Jeffrey Cummings - MD

Institutional: UNLV | Research Professor, School of Integrated Health Sciences 

  • Previously: (until 2019)  
    • Founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. 
    • Director of Alzheimer’s Disease Research, Center for Neurotherapeutics, both at UCLA.
  • Ranked in the top 0.01% of scientists and #5 in Alzheimer's disease research in a recent publication in PLoS Biology.
  • Published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials. Lead author on: "Drug development in Alzheimer's disease: the path to 2025" 

Interview Goal
This conversation will look at the big questions the FDA will want panel members to address:
  • Do the efficacy data demonstrate in a convincing and meaningful way that aducanumab slows the progression of Alzheimer’s disease in patients with early or mild symptoms?
  • Is aducanumab sufficiently safe to administer to these Alzheimer’s patients? Specifically, are the reported cases of brain swelling and bleeding attributed to aducanumab a safety risk that can be adequately monitored and managed?
  • Does the overall clinical benefit of aducanumab outweigh its safety risk enough to support the drug’s approval to treat Alzheimer’s patients?

Are You Interested In These Questions?

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.